https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:75 Wed 11 Apr 2018 09:52:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:6939 Sat 24 Mar 2018 10:46:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1438 Sat 24 Mar 2018 08:28:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:2260 US $382; odds ratio [OR], 3.5; 95% confidence interval [CI], 2.6-4.7) and support for attending international conferences (OR, 5.4; 95% CI, 3.9-7.4). The strongest associations were seen for acting as a paid consultant to industry (OR, 9.0; 95% CI, 3.9-20.4) and for membership on advisory boards (OR, 6.9; 95% CI, 5.1-9.6). There was a strong relationship between research collaboration and accumulation of industry ties. For 1 additional tie the OR was 2.2 (95% CI, 1.2-3.8) and rose to 6.3 (95% CI, 3.5-11.1) with 3 ties and 41.8 (95% CI, 14.5-143.4) with 6 or more ties. Conclusions: Medical specialists who have research relationships with the pharmaceutical industry are much more likely to have multiple additional ties than those who do not have research relationships. Institutional review should discourage clinical researchers from developing multiple ties.]]> Sat 24 Mar 2018 08:27:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:213 Sat 24 Mar 2018 07:43:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:389 Sat 24 Mar 2018 07:42:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:3850 Sat 24 Mar 2018 07:19:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10522 Mon 23 Sep 2019 11:09:01 AEST ]]>